Back to search

Peptide record

TPDB08982

P18 Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08982
P18
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP dbAMP 3.0 iACP-DRLF pep-lab Antifungipept CAFPdb APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KWKLFKKIPKFLHLAKKF
Physicochemical Analysis
C118H186N28O19
RNDCEQGMSTYV
K
2300.95
11.29
8
0
9
+7
0.94
-0.383
92.22
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
239.03
0
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
3
L
7
K
0
M
3
F
1
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 3 K: 7 M: 0 F: 3 P: 1 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
18
C118H186N28O19
2300.95
11.29
+7
0.94
-0.383
Free
L
Linear
Free
Antibacterial
Bovine lactoferrin (Lf-B) Synthetic peptide
Evidence Records 14 records
Evidence 1 Activity

Activity

92.2 ± 1.02% cell viability at 10 µM
Anticancer

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

71.1 ± 2.84% cell viability at 20 µM
Anticancer

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 3 Activity

Activity

50 ± 3.09% cell viability at 40 µM
Anticancer

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 4 Activity

Activity

31.5 ± 1.49% cell viability at 60 µM
Anticancer

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 5 Activity

Activity

13.8 ± 1.44% cell viability at 80 µM
Anticancer

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 6 Activity

Activity

86 ± 0.57% cell viability at 10 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 7 Activity

Activity

63.8 ± 0.8% cell viability at 20 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 8 Activity

Activity

47.5 ± 1.66% cell viability at 40 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 9 Activity

Activity

26.9 ± 0.5% cell viability at 60 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 10 Activity

Activity

6.5 ± 1.07% cell viability at 80 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2010
Evidence 11 Activity

Activity

0% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The Design and Construction of K11: A Novel ?-Helical Antimicrobial Peptide | Int J Microbiol | 2012
Evidence 12 Activity

Activity

0% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. | J Pept Res | 2001
Evidence 13 Activity

Activity

IC50
Toxicity
75.0 µM
Cytotoxic
IC50 | 75.0 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. | J Pept Res | 2001
Evidence 14 Hemolysis

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.